Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
04 févr. 2021 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
10 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
SomaLogic Announces New Collaboration with FDA to Advance Biosimilar Development
29 oct. 2020 10h00 HE
|
SomaLogic, Inc.
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the...
Global Non-alcoholic Steatohepatitis Biomarkers Market Accounted for US$ 556.6 Billion in 2019 and is Estimated to be US$ 8177.9 Billion by 2029 and is Anticipated to Register a CAGR of 31.3%
18 août 2020 10h05 HE
|
PMI
Covina, CA, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The report "Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers,...
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
12 août 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
20 avr. 2020 16h06 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h05 HE
|
Fluidigm Corporation
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates...
CENTOGENE Signs New Collaboration with PTC Therapeutics for Global Diagnostic Testing Program
18 nov. 2019 08h00 HE
|
Centogene AG
CAMBRIDGE, Ma. and ROSTOCK, Germany, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and...
CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.
13 nov. 2019 03h23 HE
|
Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2019 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...
Fluidigm Announces Third Quarter 2019 Financial Results
05 nov. 2019 16h05 HE
|
Fluidigm Corporation
Third quarter revenue decreased 8.5 percent to $26.5 million; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass...